The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Wyngaarden James B since 2005.
The trader's CIK number is 1022940.
At the time of the last reporting, Wyngaarden James B was the Director of Idera Pharmaceuticals, Inc.. (stock ticker symbol IDRA).
Also see all insider trading activities at Idera Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2008 | IDRA | 465 | $5,248 | 27,284 | $307,722 | 27,284 | $114,272 |
| 2007 | IDRA | 2,439 | $12,496 | 0 | $0 | 0 | $0 |
| 2006 | IDRA | 7,574 | $8,748 | 0 | $0 | 0 | $0 |
| 2005 | IDRA | 32,612 | $16,252 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2008-06-12 | IDRA | Sale | 1,284 | 14.50 | 18,618 |
| 2008-06-10 | IDRA | Option Ex | 1,284 | 8.00 | 10,272 |
| 2008-05-16 | IDRA | Sale | 5,990 | 14.79 | 88,592 |
| 2008-05-16 | IDRA | Option Ex | 5,990 | 4.00 | 23,960 |
| 2008-03-13 | IDRA | Option Ex | 9,704 | 4.00 | 38,816 |
| 2008-03-14 | IDRA | Option Ex | 10,306 | 4.00 | 41,224 |
| 2008-03-13 | IDRA | Sale | 9,704 | 10.00 | 97,040 |
| 2008-03-14 | IDRA | Sale | 10,306 | 10.04 | 103,472 |
| 2008-01-02 | IDRA | Buy | 465 | 11.29 | 5,248 |
| 2007-10-01 | IDP | Buy | 230 | 7.61 | 1,749 |
| 2007-07-02 | IDP | Buy | 761 | 5.58 | 4,249 |
| 2007-01-03 | IDP | Buy | 1,448 | 4.49 | 6,498 |
| 2006-10-10 | IDP | Buy | 632 | 3.56 | 2,250 |
| 2006-07-07 | IDP | Buy | 968 | 3.36 | 3,249 |
| 2006-04-05 | IDP | Buy | 5,974 | .54 | 3,249 |
| 2005-10-03 | IDP | Buy | 4,390 | .57 | 2,502 |
| 2005-07-01 | HBY | Buy | 9,454 | .48 | 4,500 |
| 2005-07-01 | HBY | Buy | 9,454 | .48 | 4,500 |
| 2005-04-01 | HBY | Buy | 9,314 | .51 | 4,750 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Wyngaarden James B (Director of Idera Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.